Poolbeg Pharma, named after the infamous Red & white towers has been working on some very exciting new ideas including a new cancer immunity drug and a potential weight loss tablet. But most early drug developments fail to make it to the final round of testing on humans because it’s so risky and so expensive.  And what does a pharma company like Poolbeg make of the EU-US trade deal with its 15% tariffs thus far? Jeremy Skillington, is the chief executive of Poolbeg pharma and joined Joe Lynam on the show this morning.